Artelo Advances Glaucoma Candidate with Phase 2 Trial Initiation
Event summary
- Artelo Biosciences dosed the first patient in its Phase 2 DREAM study evaluating ART27.13 for glaucoma treatment.
- The trial is funded by Glaucoma UK and HSC R&D Division, with Professor Augusto Azuara-Blanco leading the research.
- ART27.13 is an orally administered synthetic cannabinoid targeting peripheral CB1/CB2 receptors to modulate intraocular pressure.
- Initial results from the DREAM study are anticipated in Q4 2026.
The big picture
Artelo’s expansion into ophthalmology with ART27.13 reflects a strategic pivot from its core focus on cancer and pain indications. The Phase 2 trial represents a high-risk, high-reward opportunity to validate the drug’s peripherally selective mechanism in a $6 billion glaucoma market where existing treatments face significant limitations. Success could position Artelo as a key player in ocular therapeutics, though competition remains intense with established players like Novartis and Allergan.
What we're watching
- Clinical Efficacy
- Whether ART27.13 can demonstrate meaningful intraocular pressure reduction without psychotropic side effects.
- Regulatory Pathway
- The pace at which Artelo advances ART27.13 through subsequent clinical phases given positive Phase 2 data.
- Market Differentiation
- How Artelo positions ART27.13 against existing glaucoma therapies, particularly topical treatments with adherence challenges.